SSE Ticker: 688198

Beijing Balance Medical Technology Co., Ltd.

佰仁医疗

Authorized Representative: 金磊

Board: Star Market

Industry Classification: Biomedicine

The pharmaceutical and biological industry has a net outflow of 2.855 billion yuan today, and the net outflow of 6 shares exceeds 100 million yuan.

Post date May 13, 2022 — 19:02 Post Lock

Bairen Medical (688198): Legal Opinion of Shanghai Junlan Law Firm on the 2021 Annual General Meeting of Beijing Bairen Medical Technology Co., Ltd. CFi.CN

Post date May 12, 2022 — 20:12 Post Lock

The average share price of the Science and Technology Innovation Board is 30.40 yuan, and the share price of 8 shares exceeds 300 yuan_Oriental Fortune Net

Post date May 10, 2022 — 18:53 Post Lock

The average share price of the Science and Technology Innovation Board is 30.40 yuan, and the share price of 8 shares exceeds 300 yuan.

Post date May 10, 2022 — 18:53 Post Lock

GF Shengjin Mixed A Net Worth Up 5.20%

Post date April 30, 2022 — 09:33 Post Lock

GF Shengjin's mixed C net worth rose 5.20%

Post date April 30, 2022 — 09:33 Post Lock

The 100 yuan shares of the Science and Technology Innovation Board reached 55 Hemai shares with the highest share price_Oriental Fortune Net

Post date April 29, 2022 — 18:42 Post Lock

The performance is still high! The 2021 annual report profits of 44 CSI Medical shares increased by 32%! 1st Quarterly Report Gao Liang Continues-Funds-Finance

Post date April 28, 2022 — 11:27 Post Lock

GF Shengjin Mixed A Net Worth Up 4.46%

Post date April 28, 2022 — 09:39 Post Lock

GF Shengjin's mixed C net worth rose 4.46%

Post date April 28, 2022 — 09:39 Post Lock

Bairen Medical (688198.SH) plans to pay 5 yuan per 10 to 4 distributions in 2021

Post date April 26, 2022 — 20:37 Post Lock

Ranking of high-priced stocks on the Science and Technology Innovation Board

Post date April 26, 2022 — 19:01 Post Lock

Fuanda Healthy Life Mixed A Net Worth Down 3.91%

Post date April 26, 2022 — 07:06 Post Lock

Orient Securities maintains Bairen Medical's buy rating: ophthalmic bio-patches have completed research and development and gradually entered the harvest period. The target price is 207.59 yuan.

Post date April 25, 2022 — 11:46 Post Lock

Orient Securities maintains Bairen Medical's buy rating: the enrollment of ophthalmic biological patches has been completed, and the research and development has gradually entered the harvest period. The target price is 207.59 yuan per Jingwang

Post date April 25, 2022 — 11:42 Post Lock

Bairen Medical's net profit in the first quarter of 2022 was 13.6069 million, an increase of 53.54% year-on-year, and share-based payment expenses decreased year-on-year.

Post date April 24, 2022 — 23:51 Post Lock

Orient Securities gives Bairen Medical a buy rating: R&D progresses in great strides, and performance continues to maintain rapid growth

Post date April 22, 2022 — 15:21 Post Lock

Orient Securities gave Bairen Medical a Buy rating: R&D progressed with great strides and performance continued to maintain rapid growth – yqqlm

Post date April 22, 2022 — 15:21 Post Lock

1904 companies announce annual dividend plans_ Securities Times Network

Post date April 22, 2022 — 10:19 Post Lock

GF Shengjin's mixed C net worth fell 3.67%

Post date April 22, 2022 — 09:13 Post Lock

Want to see more data? Registered subscribers can see all the data.